CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Rosiglitazone +1 moredrug
Likely dose
Rosiglitazone 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00413335
NCT00413335N/ACompleted
CompareCT.gov

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Yale University·interventional·Posted Dec 19, 2006·Updated Jul 22, 2013

In Brief

A clinical study evaluating Rosiglitazone and Placebo for Obesity and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 19, 2006
Enrollment StartNov 1, 2005
Primary CompletionSep 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.5 years ago

Interventions

Rosiglitazonedrug

2mg to begin then 4mg, twice daily for 4 months

Placebodrug

Subject receives placebo.